The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial

This study evaluates the clinical benefit of pegylated liposomal doxorubicin (PLD) in patients with metastatic breast cancer (MBC), previously treated with conventional anthracyclines. Seventy-nine women with MBC previously treated with anthracyclines received PLD 50 mg m(−2) every 4 weeks. All pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Batran, S-E, Bischoff, J, von Minckwitz, G, Atmaca, A, Kleeberg, U, Meuthen, I, Morack, G, Lerbs, W, Hecker, D, Sehouli, J, Knuth, A, Jager, E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361305/
https://www.ncbi.nlm.nih.gov/pubmed/16685267
http://dx.doi.org/10.1038/sj.bjc.6603158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361305/
https://www.ncbi.nlm.nih.gov/pubmed/16685267
http://dx.doi.org/10.1038/sj.bjc.6603158

Ejemplares similares